Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors

Summary

This is a Phase1, single-arm study for treatment. This is a prospective multicenter, multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which in the judgement of the Investigator, no standard alternative therapy is available.

Timeline

Start

2022-10-03

Primary completion

2023-08-01

Completion

2024-04-10

Drugs

Indications